The Journal of Pharmacology and Experimental Therapeutics / JPET (ASPET)

The Journal of Pharmacology and Experimental Therapeutics / JPET (ASPET) JPET provides broad coverage of all aspects of pharmacology, furthering research into the interaction of chemicals with biological systems.

http://jpet.aspetjournals.org/ A leading research journal in the field of pharmacology, JPET provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and dispos

ition, chemotherapy, and toxicology. The Special Libraries Association has included JPET in its DBIO 100, the "100 most influential journals of biology and medicine over the 100 years of the association. The Journal of Pharmacology and Experimental Therapeutics is a journal of the American Society for Pharmacology and Experimental Therapeutics.

The individual Facebook accounts for our journal pages will be closing next week, and will instead be combined into one ...
01/22/2026

The individual Facebook accounts for our journal pages will be closing next week, and will instead be combined into one account for all of your ASPET journal news! Follow our page at https://www.facebook.com/ASPETJournals/ for the latest editorials, HTAs, Calls for Papers, Special Collections, and more!

01/20/2026

Phosphodiesterase 7 Inhibition reduces L-DOPA-induced dyskinesias in parkinsonian non-human primates. L-DOPA-induced dyskinesia (LID) is a common adverse effect that causes uncontrolled movements in Parkinson's disease patients. The treatment for LID involves either adjusting the dose of L-DOPA or taking the old antiviral medication amantadine, which has a high rate of undesirable adverse effects. Neither option is ideal; therefore, there is a need for more effective therapies to alleviate LID. A collaboration between a group at Emory University and Omeros Corp. examined a novel PDE7 inhibitor in a preclinical model of Parkinson's disease. The inhibitor, OMS-401, significantly reduced LID without any adverse effects. Interestingly, the middle dose chosen provided the greatest effect, and has a pharmacokinetic profile suggesting that a once-daily oral treatment is possible. These data suggest that inhibition of PDE7 in the striatum is a promising target for treating LID.

Read the research: https://ow.ly/ubY250XXkZ4

BRG1 targeting overcomes ABCC-based multidrug resistance induced by paclitaxel. Paclitaxel is a widely used chemotherape...
01/13/2026

BRG1 targeting overcomes ABCC-based multidrug resistance induced by paclitaxel. Paclitaxel is a widely used chemotherapeutic; however, drug resistance is a serious problem. Resistance arises in 50% or more of all tumors treated with paclitaxel, and most of the tumors after relapse are resistant to paclitaxel. Therefore, there is an unmet need in preventing paclitaxel resistance.

A group from the University of Lodz, Poland, utilized a genomic approach to identify that BRG1 increases the expression of drug transport proteins that pump paclitaxel into lysosomes, rendering it inactive. They further demonstrate that inhibiting BRG1 with a small molecule or degrading the mRNA leads to an increase in cytoplasmic paclitaxel, resulting in an enhanced drug effect and greater tumor pe*******on. Furthermore, inhibiting BRG1 sensitized cells to other chemotherapeutic agents. These data suggest that inhibition of BRG1 could be a novel mechanism for combating paclitaxel resistance and enhancing the potency of chemotherapeutic agents.

Read the research: https://jpet.aspetjournals.org/article/S0022-3565(25)40285-7/abstract

Congratulations to the 2026 recipients of an ASPET Editorial Fellowship. This program offers senior post-doctoral fellow...
01/12/2026

Congratulations to the 2026 recipients of an ASPET Editorial Fellowship. This program offers senior post-doctoral fellows and junior faculty members the opportunity to build important skills as a peer reviewer and as an editor.

JPET is planning a collection titled, “Gene and Cell-Based Therapeutics for Disorders of Maladaptive Neuroplasticity," ...
12/17/2025

JPET is planning a collection titled, “Gene and Cell-Based Therapeutics for Disorders of Maladaptive Neuroplasticity," profiling original research in all areas associated w/ gene and cell-based therapeutics for neurological disorders driven by maladaptive neuroplasticity: https://ow.ly/esRy50XJP0s

Harlie McKelvey, a Neuroscience PhD candidate, is the Journal of Pharmacology and Experimental Therapeutics Highlighted ...
12/10/2025

Harlie McKelvey, a Neuroscience PhD candidate, is the Journal of Pharmacology and Experimental Therapeutics Highlighted Trainee Author for December 2025.

When dependent people stop taking opioids, they don't just feel sick, they also experience serious sleep problems which can last for a long time. McKelvey's research focuses on understanding how repeated, spontaneous opioid withdrawal affects overall sleep architecture and brain activity.

"I hope that my research will shift the field toward recognizing withdrawal-related sleep disturbances as a meaningful pharmacological target,” she shared.

➡️ Read the article here: https://doi.org/10.1016/j.jpet.2025.103766.

12/09/2025

According to National Institute on Alcohol Abuse and Alcoholism, alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, alcohol addiction, and the colloquial term, alcoholism. Considered a brain disorder, AUD can be mild, moderate, or severe.

Given the prevalence of AUD in the United States and around the world, there is a need to develop new, effective and safe therapies. A group from Texas Tech University Health Sciences Center synthesized a novel nonantibiotic minocycline (MINO) derivative, 10-butyl ether minocycline (BEM), with the hope of retaining its pleiotropic effects, such as the anti-inflammatory, antioxidant, antimigratory, anti- matrix metalloproteinase (MMP), and neuroprotective effects of MINO, while minimizing side effects such as antibiotic resistance and gut dysbiosis. This team showed that BEM did exhibit pleiotropic effects, whereas there was complete loss of antimicrobial action. Also, BEM decreased oxidative stress while maintaining mitochondrial safety.

Thus, BEM presents an advancement in the development of a promising candidate and should inform the design of next-generation therapeutics with multimodal mechanisms to treat AUD and perhaps other neuroimmune-inflammatory pathologies.

Read their research in our Editor's Choice: https://ow.ly/Rhx050XFLb6

The Journal of Pharmacology and Experimental Therapeutics is planning a new special collection titled, “Gene and Cell-Ba...
12/03/2025

The Journal of Pharmacology and Experimental Therapeutics is planning a new special collection titled, “Gene and Cell-Based Therapeutics for Disorders of Maladaptive Neuroplasticity."

This special collection seeks to profile original research in all areas associated with gene and cell-based therapeutics for neurological disorders driven by maladaptive neuroplasticity. The scope includes basic, translational, preclinical, as well as clinical research that focus on mechanistic understanding and therapeutic development of gene and cell-based strategies to target maladaptive neuroplasticity-associated neurological disorders.

Learn more and submit your work!

https://ow.ly/5jPX50XASgJ

According to the Centers for Disease Control, drug overdoses are one of the leading causes of injury death in adults and...
12/02/2025

According to the Centers for Disease Control, drug overdoses are one of the leading causes of injury death in adults and have risen over the past several decades in the United States. This is attributed, in part, to the widespread availability of fentanyl and its analogs. Thus, there is a constant yet urgent need to identify therapeutic agents and/or approaches to fight against this epidemic.

As a complementary strategy to current overdose reversal agents, monoclonal antibodies (mAbs) are in development as therapeutics for prevention and reversal of fentanyl overdose. In a recent study, a research team from the University of Minnesota Medical School, Minneapolis, Minnesota, tested the anti-fentanyl mAb (referred to as HY6-F9) for reversal of fentanyl-induced respiratory arrest (apnea) in a porcine model, relative to naloxone. These researchers showed that HY6-F9 reversed fentanyl-induced apnea in pigs, and caused rapid redistribution of fentanyl into serum. Also, Fentanyl was 99% bound by monoclonal antibodies and showed no activity at the opioid receptor. Together, these results demonstrate the efficacy of an anti-fentanyl mAb as a treatment to reverse fentanyl overdose.

https://ow.ly/SZpJ50XAGp6

Address

Bethesda, MD
20852

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Telephone

(301) 634-7060

Website

Alerts

Be the first to know and let us send you an email when The Journal of Pharmacology and Experimental Therapeutics / JPET (ASPET) posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to The Journal of Pharmacology and Experimental Therapeutics / JPET (ASPET):

Shortcuts

Share

Category